FibroGen, Inc. (NASDAQ:FGEN) Q4 2022 Earnings Call Transcript

I think at the end of the day, the data will be the data. But I think we’re starting — the first readout you’re going to get is the most difficult patient population, the non-ambulatory population who’s already lost the most function, and the signal to noise for the endpoints are the most challenging. Later, we’ll get LELANTOS-2, I think because these patients have more function at baseline, it will be a little bit more clear cut in terms of evaluating the efficacy.

Annabel Samimy: Okay. Great. Thank you so much.

Operator: Thank you. At this time, I’d like to turn the call back over to Enrique Conterno for closing remarks. Sir?

Enrique Conterno: Thank you very much to everyone for your participation in today’s investor call and your interest in FibroGen and very much enjoy the rest of your day. Thank you very much.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.